Details of the Drug

General Information of Drug (ID: DMMJZYC)

• Drug Name: CH-223191
• Synonyms: 301326-22-7; CH 223191; CH223191; UNII-HYE7315Z4C; HYE7315Z4C; CHEMBL1743245; AhR Antagonist; 2-methyl-N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]pyrazole-3-carboxamide; 1-Methyl-N-[2-methyl-4-[2-(2-methylphenyl)diazenyl]phenyl-1H-pyrazole-5-carboxamide; 2-methyl-N-[2-methyl-4-(2-methylphenyl)azophenyl]-3-pyrazolecarboxamide; (E)-1-methyl-N-(2-methyl-4-(o-tolyldiazenyl)phenyl)-1H-pyrazole-5-carboxamide; 1-methyl-N-{2-methyl-4-[(E)-(2-methylphenyl)diazenyl]phenyl}-1H-pyrazole-5-carboxamide; 2-Methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide; CBDivE_007629; SCHEMBL363547; DTXSID5058698; AOB1977; EX-A771; SYN5007; CHEBI:125508; HMS3412G22; HMS3676G22; HMS3750E07; BCP12814; ZINC4762981; BDBM50525572; MFCD00377884; s7711; SBB081907; STK837883; 2-Methyl-2H-pyrazole-3-carboxylic acid-(2-methyl-4-o-tolyl-azophenyl)-amide; AKOS000629906; AKOS026750492; ZINC100550218; ZINC254429865; CCG-267843; CS-3905; MCULE-3225752823; 1H-Pyrazole-5-carboxamide, 1-methyl-N-(2-methyl-4-((2-methylphenyl)azo)phenyl)-; 1H-Pyrazole-5-carboxamide, 1-methyl-N-(2-methyl-4-(2-(2-methylphenyl)diazenyl)phenyl)-; AC-32878; AS-16374; HY-12684; QC-11824; FT-0696668; X3558; J-017795; BRD-K22314899-001-01-6; Q27216129; Q27280162; 1-methyl-N-{2-methyl-4-[2-(2-methylphenyl)diazen-1-yl]phenyl}-1H-pyrazole-5-carboxamide; N-{2-methyl-4-[(2-methylphenyl)diazenyl]phenyl}(1-methylpyrazol-5-yl)carboxami de

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Investigative	[1]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 333.4
  Topological Polar Surface Area (xlogp); 3.9
  Rotatable Bond Count (rotbonds); 4
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 4
• Chemical Identifiers:
  Formula: C19H19N5O
  IUPAC Name: 2-methyl-N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]pyrazole-3-carboxamide
  Canonical SMILES: CC1=CC=CC=C1N=NC2=CC(=C(C=C2)NC(=O)C3=CC=NN3C)C
  InChI: InChI=1S/C19H19N5O/c1-13-6-4-5-7-17(13)23-22-15-8-9-16(14(2)12-15)21-19(25)18-10-11-20-24(18)3/h4-12H,1-3H3,(H,21,25)
  InChIKey: LKTNEXPODAWWFM-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 3091786
  ChEBI ID: CHEBI:125508
  CAS Number: 301326-22-7
  TTD ID: DL36FJ

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aryl hydrocarbon receptor (AHR)	TT037IE	AHR_HUMAN	Antagonist	[1]

References

• [1] Novel compound 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) prevents 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor. Mol Pharmacol. 2006 Jun;69(6):1871-8.
• [2] A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer. 2005 Oct 17;93(8):876-83.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of Ikena Oncology.
• [5] ClinicalTrials.gov (NCT04069026) A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer. U.S. National Institutes of Health.
• [6] In silico identification of an aryl hydrocarbon receptor antagonist with biological activity in vitro and in vivo. Mol Pharmacol. 2014 Nov;86(5):593-608.
• [7] 1'H-Indole-3'-Carbonyl-Thiazole-4-Carboxylic Acid Methyl Ester Blocked Human Glioma Cell Invasion via Aryl Hydrocarbon Receptor's Regulation of Cytoskeletal Contraction. Biomed Res Int. 2020 Oct 3;2020:2616930.
• [8] 6-Formylindolo(3,2-b)carbazole induced aryl hydrocarbon receptor activation prevents intestinal barrier dysfunction through regulation of claudin-2 expression. Chem Biol Interact. 2018 May 25;288:83-90.